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Abstract
Owing to the high levels of antiapoptotic B-cell lymphoma 2 (BCL-2) family members observed in several cancers,
there has been a major effort to develop inhibitors of the BCL2-family as chemotherapeutic agents. Of the different
members in the BCL-2 family, myeloid cell leukemia sequence 1 (MCL-1) is commonly amplified in human tumors and
is associated with their relapse and chemoresistance. As a result, specific inhibitors of MCL-1 are being designed to
treat resistant tumors. However, there is increasing evidence for other nonapoptotic roles of the BCL-2 family, ranging
from ionic homeostasis and autophagy to the regulation of fission-fusion dynamics in subcellular organelles, includ-
ing the endoplasmic reticulum and mitochondria. In this study, we characterize the specificity of two novel putative
MCL-1 inhibitors, BI97C1 (Sabutoclax) and BI112D1, in inducing apoptosis in a BAX/BAK-dependent manner and in
an MCL-1–dependent system. In addition to their being proapoptotic, these inhibitors also cause enhanced mito-
chondrial fragmentation that accompanies a time-dependent loss of optic atrophy 1 (OPA1), suggesting an impair-
ment of mitochondrial fusion. This mitochondrial fragmentation occurs independently of dynamin-related protein 1
(DRP1)–mediated fission activity and, unlike most apoptotic stimuli, occurs upstream of and/or independent of BAX,
BAK, and other BH3-only proteins. Furthermore, thismitochondrial fragmentation occurred rapidly and preceded other
hallmarks of apoptosis, including the loss in mitochondrial membrane potential and the release of cytochrome c.
Although such mitochondrial fragmentation did not deplete total cellular adenosine triphosphate (ATP) or alter other
mitochondrial complexes, there was significant accumulation of reactive oxygen species.
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Introduction
Several diseases including cancer, autoimmunity, and neurodegeneration
have been attributed to a defective/ineffective apoptotic program, a
major mechanism by which cells in the body undergo self-destruction.
Apoptosis can be triggered by the activation of death receptors on the
cell surface (extrinsic pathway) or by perturbation of mitochondrial
integrity (intrinsic pathway) [1,2]. Apoptosis is primarily regulated by
the B-cell lymphoma 2 (BCL-2) family of proteins, which comprise
the apoptotic effector molecules, BAX and BAK, which are activated
by BH3-only proteins (including BIM, BAD, PUMA, and NOXA)
and antagonized by antiapoptotic BCL-2 family proteins (including
BCL-2, BCL-XL, BCL-w, myeloid cell leukemia sequence 1 (MCL-1),
and BCL2A1) [3,4]. BCL-2 family members act primarily to control
the integrity of the outer mitochondrial membrane, thereby regulating
cellular susceptibility to apoptosis induced by the intrinsic pathway
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[1]. As most cancer chemotherapeutic agents induce apoptosis by activa-
tion of the intrinsic pathway andmany cancers exhibit high levels of anti-
apoptotic BCL-2 family members, there has been a major effort to
develop inhibitors of the BCL2-family.
Despite the many claims in the literature of their supposed speci-
ficity, the vast majority of these putative BCL-2 family inhibitors are
nonspecific, with two key exceptions, ABT-737 and its orally active
and metabolically more stable analog, ABT-263 (Navitoclax), the latter
of which has recently entered clinical trials for the treatment of various
hematological malignancies [5–10]. Both ABT-737 and ABT-263
inhibit BCL-2, BCL-XL, and BCL-w but do not inhibit MCL-1 or
BCL2A1 [6,7]. As MCL-1 is commonly amplified in human tumors
and is associated with tumor relapse and chemoresistance, particularly
to ABT-737 [8,11–15], specific inhibitors of MCL-1 could be a very
valuable addition to aid in treating chemoresistant tumors.
In addition to their role in the regulation of apoptosis, there is in-
creasing evidence for nonapoptotic roles of the BCL-2 family [16,17]
in particular in the regulation of mitochondrial structure and partial
control of mitochondrial fusion and fission [18,19]. In this regard, a
recent report has proposed that one isoform of MCL-1 resides in the
outer mitochondrial membrane and antagonizes apoptosis, whereas an
N-terminal truncated isoform resides in the mitochondrial matrix where
it is required for normal mitochondrial fusion, adenosine triphosphate
(ATP) production, and membrane potential [20]. However, the precise
mechanisms by which MCL-1 regulates mitochondrial structure and/or
function are yet to be determined.
In this study, we use an MCL-1–dependent non–small cell lung
cancer cell line, H23, to characterize the specificity of putative novel
MCL-1 inhibitors [14]. Owing to the limitations of ABT-737 and
ABT-263 to inhibit MCL-1, nuclear magnetic resonance (NMR) bind-
ing assays and computational docking studies were used to identify
apogossypol derivatives with pan-BCL-2 family inhibitory properties
[21,22]. One of these molecules, BI-97C1 (Sabutoclax), is an optically
pure apogossypol derivative with improved in vitro and in vivo efficacy
and inhibits tumorigenesis in various models of prostate cancer [23,24].
In addition, one optically pure apogossypolone derivative, BI112D1
((−)BI97D6), is also a potent pan-active BCL-2 family inhibitor and
exerts antitumor activity in a prostate cancer xenograft model in mice
[25,26]. Both BI97C1 and BI112D1 induced apoptosis in a BAX/
BAK-dependent manner and inMCL-1–dependent cells. These inhibi-
tors also caused a time-dependent loss of optic atrophy 1 (OPA1) that
accompanied enhanced mitochondrial fragmentation as well as an in-
creased mitochondrial accumulation of reactive oxygen species (ROS).
Materials and Methods
Cell Culture
Wild-type (WT) and BAX/BAK double knockout (DKO) mouse
embryonic fibroblasts (MEFs) from Dr A. Strasser (Walter and Eliza
Hall Institute, Melbourne, Australia) were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 5 mM L-glutamine and
10% fetal calf serum (all from Life Technologies Inc, Paisley, United
Kingdom). H23 cells from Prof. C. Pritchard (University of Leicester,
Leicester, United Kingdom) were cultured in RPMI 1640 medium
supplemented with 10% fetal calf serum and 5 mM L-glutamine.
Reagents and Plasmids
BI97C1 and BI112D1 were synthesized as described [22,26].
ABT-263 was obtained from Selleck Chemicals Co (Houston, TX).
Antibodies against cytochrome c, HSP60, OPA1, mitofusin 1 (MFN1),
and dynamin-related protein 1 (DRP1) from BD Biosciences (Oxford,
United Kingdom), MFN2, ATP5A, UQCRC2, SDHB, and tubulin
fromAbcam (Cambridge, United Kingdom), and COX4 andNDUFA9
from Santa Cruz Biotechnology, Inc (Dallas, TX) were used. DRP1
K38A was a kind gift from Dr Bampton (MRC Toxicology Unit,
Leicester, United Kingdom). MitoTracker Deep Red, MitoSOX
Red, and tetramethylrhodamine ethyl ester (TMRE) were from Molec-
ular Probes, Inc (Eugene, OR). All other reagents, unless mentioned
otherwise, were from Sigma-Aldrich Co (St Louis, MO).
Transient Overexpression and siRNA Knockdowns
For transient transfections, cells were transfected using TransIT-LT-1
transfection reagent (Mirus Bio LLC, Madison, WI) and left for
48 hours, according to the manufacturer’s instructions. For siRNA
knockdowns, cells were reverse transfected with oligoduplexes (Life
Technologies or Thermo Scientific, Waltham, MA), using Interferin
Reagent (Polyplus Transfection Inc, New York, NY), according to the
manufacturer’s protocol and processed 72 hours after transfection. Cells
were reverse transfectedwith 10 nMDRP1 (IDNo. s19560),OPA1 (ID
No. s9850), MFN1 (ID No. s31220), BCL-XL (ID No. s1920), BCL-w
(ID No. s1924), MCL-1 (ID No. s8583), BIM (ID No. s195011), or
NOXA (ID No. L-005275).
Cytochrome c Release and Western Blot Analysis
Cytochrome c release experiments were carried out in cells exposed to
different drugs for the indicated times and assessed as previously described
[27]. Western blots were carried out according to standard protocols [10].
Briefly, 50 μg of total protein lysate was subjected to sodium dodecyl
sulfate–polyacrylamide gel electrophoresis. Subsequently, proteins were
transferred to nitrocellulose membrane and protein bands were visual-
ized with ECL reagents (GE Healthcare, Bucks, United Kingdom).
Microscopy
For immunofluorescent staining, cells grown on coverslips were
fixed with 4% (vol/vol) paraformaldehyde, permeabilized with 0.5%
(vol/vol) Triton X-100 in phosphate-buffered saline, and followed by
incubations with primary antibodies and analyzed as previously de-
scribed [28]. For monitoring mitochondrial fragmentation and changes
in mitochondrial membrane potential, cells were stained for 30 minutes
with 200 nM MitoTracker Deep Red and 500 nM TMRE before
image acquisition. For electron microscopy, cells were fixed and pro-
cessed as previously described [28]. Electron micrographs were re-
corded using a Megaview 3 digital camera and iTEM software
(Olympus Soft Imaging Solutions GmbH, Münster, Germany) in a
Jeol 100-CXII electron microscope (Jeol UK Ltd, Welwyn Garden
City, United Kingdom).
Flow Cytometry
Loss in mitochondrial membrane potential (ψm) was assessed as
described previously by staining cells with TMRE, a lipophilic fluo-
rescent dye that accumulates in the mitochondria in proportion to
the membrane potential [27]. Cell death was assessed by phosphatidyl-
serine (PS) externalization and staining with Annexin V–fluorescein
isothiocyanate as described previously [27]. For measuring the extent
of ROS accumulation in the mitochondria, cells exposed to DMSO
or the inhibitors for the indicated times were incubated for 10 minutes
at 37°C with 5 μM MitoSOX Red reagent and assessed for increase
in fluorescence intensity.
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Measurement of Total Cellular ATP
Total cellular ATP in cells exposed to the different inhibitors for
the indicated times was measured using CellTiter-Glo Luminescent
Cell Viability Assay Kit (Promega, Madison, WI), according to the
manufacturer’s instructions.
Results
ABT-263, BI97C1, and BI112D1 Induce
Concentration-Dependent Apoptosis
Since antiapoptotic members of the BCL-2 family antagonize BAX/
BAK-dependent release of cytochrome c and other apoptotic factors
from the mitochondria, we tested the specificity of the putative
MCL-1 inhibitors, BI97C1 and BI112D1, in MEFs, derived from
WT or BAX and BAK DKO mice. As a positive control, we used
ABT-263 (Navitoclax), a BCL-2 family antagonist, which has recently
entered clinical trials in patients with B cell malignancies, as it induces
cell death in a BAX/BAK-dependent manner [7,29]. In agreement with
previous data [7], ABT-263 induced a concentration-dependent cell
death (assessed by PS externalization) in WT but not in BAX/BAK
DKO MEFs (Figure 1A, left panel ). Similarly, both BI97C1 and
BI112D1 induced a concentration-dependent cell death in a BAX/
BAK-dependent manner in MEFs, although BI97C1 induced marked
cell death at 3 μM (Figure 1A, center and right panels). Thus, both
BI97C1 and BI112D1, like ABT-737 and ABT-263, kill cells spe-
cifically in a BAX/BAK-dependent manner, unlike most other putative
BCL-2 antagonists described in the literature [5,9,10].
Since BI97C1 and BI112D1 possess improved binding affinities
for MCL-1 compared with both ABT-263 and the structurally related
apogossypol [7,21,22,26], we examined their efficacy in an MCL-1–
dependent cell line, H23 [14]. Both BI97C1 and BI112D1 caused a
time-dependent induction of apoptosis, assessed by PS externalization,
which was preceded by a loss in mitochondrial membrane potential
(ψm) and accompanied by an elevation in cytosolic cytochrome c (Fig-
ure 1, B–D). Surprisingly, ABT-263 was more potent than BI112D1
in inducing cell death in H23 cells (Figure 1, B–D), suggesting that
at high concentrations it could effectively inhibit MCL-1 in these cells.
These data are compatible with the putative MCL-1 inhibitors, BI97C1
and BI112D1, inducing mitochondrial outer membrane permeabiliza-
tion (MOMP) and apoptosis by activation of the intrinsic pathway.
BI97C1 and BI112D1 Induce Extensive
Mitochondrial Fragmentation
Resistance to BCL-2 antagonists as well as other chemotherapeutic
agents is frequently due to elevated levels of MCL-1 [8,11–14]. To
our knowledge, there is currently no bona fide inhibitor of MCL-1
Figure 1. BI97C1, BI112D1, and ABT-263 induce apoptosis in a BAX/BAK-dependent manner and in MCL-1–dependent cells. (A) WT (bold
lines) and BAX/BAK DKO MEFs (dashed lines) were exposed to the indicated concentrations of ABT-263, BI97C1, or BI112D1 for 24 hours
and analyzed for PS externalization. (B) H23 cells exposed to 10 μMABT-263, BI97C1, or BI112D1 for the indicated times were fractionated
to collect the cytosol-enriched supernatant (S) and the mitochondria-enriched pellet (P), which were then analyzed for cytochrome c
by Western blot analysis. H23 cells exposed to 10 μM ABT-263, BI97C1, or BI112D1 for the indicated times were analyzed for (C) loss in
mitochondrial membrane potential (ψm) or (D) changes in PS externalization.
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Figure 2. Inhibitors of MCL-1 induce rapid and extensive fragmentation of the mitochondrial network. (A) H23 cells exposed to 10 μM
ABT-263, BI97C1, or BI112D1 for the indicated times and immunostained for HSP60 exhibited extensive mitochondrial fragmentation
(scale bar, 10 μm). (B) H23 cells exposed to DMSO (first panel), ABT-263 (second panel), BI97C1 (third panel), or BI112D1 (fourth panel)
all at 10 μM for 8 hours and subjected to electron microscopy revealed a fragmented mitochondrial network in all but the DMSO-treated
cells. The arrow in the fourth panel indicates reorganization of the endoplasmic reticulum induced by BI11D1 (scale bar, 2 μm). (C) H23
cells reverse transfected for 16 hours with siRNA against MCL-1, but not BCL-XL or BCL-w, showed altered mitochondrial structure
(scale bar, 10 μm).
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described in the literature. Since both BI97C1 and BI112D1, like
ABT-263, induced apoptosis inMCL-1–dependent H23 cells, primarily
through the mitochondrial pathway, we examined their effects on
mitochondrial structure and function. All compounds caused a dramatic
time-dependent loss of the tubular mitochondrial network accompanied
by extensive mitochondrial fragmentation, which was evident as early as
1, 2, and 8 hours after exposure to BI112D1, BI97C1, and ABT-263,
respectively (Figures 2A and 4D). The rapid induction of mitochondrial
fragmentation suggested that these inhibitors could be valuable tools to
further understand mechanisms of mitochondrial fragmentation and its
possible relationship to cell death. The fragmentation of mitochondria
by both compounds was confirmed by electron microscopy (Figure 2B).
Despite the statistical improbability of a 70-nm-thick section being cut
both coincident and parallel with the long axis of an elongate mito-
chondrion, several mitochondrial profiles with an aspect ratio >5:1 were
found in untreatedH23 cells. No such profiles were found in treated cells;
indeed, few mitochondria were found with an aspect ratio >2:1, but all
appeared to be healthy with no signs of swelling or disruption. There
were no indications of autophagy/mitophagy in any of the treated cells
(Figure 2B). Since H23 cells primarily express MCL-1 and BCL-w, with
barely detectable levels of BCL-XL and noBCL-2 [14] (FigureW1A), it is
likely that the mitochondrial fragmentation observed following these
compounds is due to the inhibition of MCL-1 and/or BCL-w. How-
ever, a recent report has also claimed a novel role for an amino-terminally
truncated isoform of MCL-1 in mitochondrial fusion in multiple cell
types [20]. In support of this observation, knockdown of MCL-1 but
not BCL-XL or BCL-w resulted in mitochondrial fragmentation (Fig-
ures 2C and W1A). However, knockdown of MCL-1 in H23 cells also
caused significant cell death, thus masking the extent of mitochondrial
fragmentation in the remaining viable cells. Taken together, our data
supported a role for MCL-1 in either promoting mitochondrial fusion
or preventing fission.
MCL-1–regulated Mitochondrial Fragmentation Is Not Due
to Enhanced DRP1-Mediated Fission
The length and continuity of the filamentous mitochondrial network
is regulated by a conserved family of GTPases that balance mito-
chondrial fission and fusion events [30]. MFN1/2 and OPA1 are essen-
tial for mitochondrial fusion, whereas Fis1 and the DRP1 are essential
for mitochondrial fission [31]. Since BI97C1, BI112D1, and ABT-263
Figure 3. BI97C1-, BI112D1-, and ABT-263–mediatedmitochondrial fragmentation is independent of DRP1-mediated fission. H23 cells were
reverse transfected with siRNA against DRP1 or transiently transfected with its dominant negative mutant (DRP1 K38A) for 48 hours. The
cells were then exposed to 10 μM ABT-263 for 8 hours, BI97C1 for 4 hours, or BI112D1 for 2 hours and subsequently immunostained with
HSP60 antibody. The efficiency of the knockdown for DRP1 is shown in Figure 4B (scale bar, 10 μm).
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all caused extensive mitochondrial fragmentation, resembling enhanced
fission, we examined if down-regulation of DRP1 would prevent mito-
chondrial fragmentation. However, neither knockdown of DRP1 nor
expression of its dominant negative mutant (K38A) affected the ability
of ABT-263, BI97C1, or BI112D1 to induce mitochondrial fragmen-
tation (Figure 3). These results suggested that these inhibitors induced
mitochondrial fragmentation independent of DRP1.
MCL-1–regulated Mitochondrial Fragmentation Could Be
Due to Loss of Mitochondrial Fusion
Recently, it was proposed that MCL-1 regulates mitochondrial frag-
mentation by facilitating mitochondrial fusion [20]. Compatible with
this was our finding that the putative MCL-1 inhibitors induced mito-
chondrial fragmentation independent of DRP1-mediated fission (Fig-
ure 3). Knockdown of either OPA1 or MFN1, two proteins involved
in mitochondrial fusion [32], resulted in similar mitochondrial frag-
mentation (Figure 4, A and B). Further examination of the effects of
ABT-263, BI97C1, and BI112D1 on key proteins involved in mito-
chondrial fusion revealed a time-dependent loss of the high molecular
weight isoforms of OPA1 (Figure 4C ) that corresponded with the
induction of extensive mitochondrial fragmentation (Figure 2A).
Taken together, these results suggest that these compounds inactivate
the ability of MCL-1 to promote mitochondrial fusion, possibly by
enhancing the proteolytic processing of OPA1.
Figure 4. Loss of OPA1 isoforms corresponds to the induction of BI97C1-, BI112D1-, and ABT-263–mediated mitochondrial frag-
mentation. (A) H23 cells, reverse transfected with siRNA against OPA1 or MFN1 for 72 hours followed by immunostaining with
HSP60, reveal a fragmented mitochondrial network (scale bar, 10 μm). (B) Western blots showing the knockdown efficiency of dif-
ferent siRNA oligoduplexes. (C) H23 cells exposed to 10 μM ABT-263, BI97C1, or BI112D1 for the indicated times and probed for
different mitochondrial fusion proteins reveal a time-dependent loss of the high molecular weight isoforms of OPA1. (D) Quanti-
fication of the percentage of cells exhibiting normal mitochondrial structure after exposure to 10 μM ABT-263, BI97C1, or BI112D1 in
H23 cells for the indicated times reveals the kinetics of extensive mitochondrial fragmentation and the loss in mitochondrial membrane
potential (ψm).
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MCL-1–regulated Mitochondrial Fragmentation Is Not
Sufficient to Induce Apoptosis
Next, we wished to explore the relationship if any between the abil-
ity of these compounds to induce mitochondrial fragmentation and
their ability to induce apoptosis. While the rate of induction of mito-
chondrial fragmentation was BI11D1 > BI97C1 >> ABT-263, the rate
of loss of ψm was BI97C1 > ABT-263 >> BI112D1, suggesting that the
mitochondrial fragmentation occurred before changes inψm, which was
most evident in cells exposed to BI112D1 (Figures 4D and W2).
ABT-263, BI97C1, and BI112D1 also induced mitochondrial frag-
mentation in both WT and BAX/BAK DKO MEFs (Figure 5A),
although they all required BAX and BAK to induce apoptosis (Fig-
ure 1A), thus placing mitochondrial fragmentation either upstream of
or independent of BAX and BAK. Previously, it had been shown that
knockdown of the BH3-only proteins, NOXA and BIM, partially res-
cued H23 cells from apoptosis induced by MCL-1 down-regulation
Figure 5. BI97C1-, BI112D1-, and ABT-263–mediated mitochondrial fragmentation occurs upstream of and/or independent of BAX/BAK
or BIM/NOXA. (A) WT and BAX/BAK DKO MEFs were exposed to 10 μM ABT-263 for 8 hours, BI97C1 for 2 hours, or BI112D1 for 2 hours
and immunostained with HSP60 to assess mitochondrial fragmentation (scale bar, 10 μm). (B) H23 cells, reverse transfected with siRNA
against BIM and NOXA, were exposed to 10 μM ABT-263 for 8 hours, BI97C1 for 4 hours, or BI112D1 for 2 hours and subsequently
immunostained with HSP60 antibody. The nucleus was stained with Hoechst 33342 (scale bar, 10 μm).
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[14]. Using a similar knockdown of BIM and NOXA to prevent apop-
tosis, all three inhibitors induced profound mitochondrial fragmenta-
tion (Figures 5B and W1B) further supporting the conclusion that
mitochondrial fragmentation occurs upstream of and/or independent
of apoptosis.
Increase in ROS Results from Perturbation of Mitochondrial
Homeostasis by Inhibitors of MCL-1
In addition to its proposed role in regulating mitochondrial fusion,
MCL-1 is also proposed to regulate ATP production, mitochondrial
membrane potential, and maintenance of oligomeric ATP synthase,
thereby preserving mitochondrial homeostasis [20]. We therefore
hypothesized that the dramatic changes in mitochondrial ultrastruc-
ture induced by the three inhibitors would disrupt mitochondrial func-
tion. Although the inhibitors neither affected ATP levels (Figure 6A)
nor certain components of electron transport chain complexes (I, II,
III, IV, and V; Figure 6B), they all induced an increase in ROS
(Figure 6C ), which suggested a possible role for ROS in MCL-1–
regulated mitochondrial fragmentation and/or apoptosis.
Discussion
Non–small cell lung cancer is the most predominant form of lung
cancer and is the primary cause of cancer deaths worldwide. Al-
though often treated with monoclonal antibodies or tyrosine kinase
inhibitors, new targeted therapies are urgently needed. BCL-2 family
members and particularly MCL-1 have been reported in primary tis-
sues from patients as well as in several non–small cell lung cancer cell
lines, suggesting that these antiapoptotic proteins may be suitable
Figure 6. MCL-1 inhibitors result in the accumulation of ROS but do not affect cellular ATP levels or mitochondrial complexes. (A) H23
cells, exposed to 10 μM ABT-263, BI97C1, or BI112D1 for the indicated times, were assessed for total cellular ATP levels. (B) Same as A,
but the cells were collected and probed for different proteins in complexes I to V. (C) H23 cells, exposed to 10 μM ABT-263, BI97C1, or
BI112D1 for 2 hours, were subsequently stained with MitoSOX Red and assessed for the mitochondrial accumulation of ROS. The dark
curve on the left side of each panel represents the control cells and the light curve represents the treated cells.
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targets for therapy [33–35]. Recently, there has been considerable
success in the development of selective inhibitors of some members
of the BCL-2 family. Some of these inhibitors, ABT-737 and its bio-
available analog, ABT-263, bind selectively to BCL-2, BCL-XL, and
BCL-w but not to MCL-1 or BCL2A1, whereas other inhibitors,
including apogossypol and obatoclax, are considered pan-BCL-2
antagonists [5,7,9,36]. To date, the selective inhibitors developed do
not target either MCL-1 or BCL2A1, and as these may be frequent
causes of chemoresistance, it is essential to develop inhibitors of these
antiapoptotic molecules [5,9,12–14,36,37]. Of the several putative
broad spectrum BCL-2 family inhibitors that we tested, apogossypol
proved rather better in inducing apoptosis in a BAX/BAK-dependent
manner [10]. In the present study, we characterize novel derivatives of
apogossypol/apogossypolone, BI-97C1 (Sabutoclax) and BI112D1 ((−)
BI97D6) [22,23,26]. Both BI97C1 and BI112D1 induced apoptosis
in a BAX/BAK-dependent manner and in an MCL-1–dependent sys-
tem (Figure 1). Although BI112D1 demonstrated better binding affin-
ities to MCL-1, BI97C1 induced rapid release of cytochrome c, loss
of mitochondrial membrane potential, and eventually PS externaliza-
tion (Figure 1, B–D). Furthermore, while BI112D1 was most selec-
tive in the induction of apoptosis in a BAX/BAK-dependent manner,
similar to ABT-263, the selectivity was more modest with BI97C1
(Figure 1A).
Recently, we identified a rapid and reversible reorganization of
endoplasmic reticulum (ER) membranes following exposure of cells to
apogossypol, which was attributed partly to the inactivation of several
BCL-2 family members, particularly MCL-1 [28,38]. In support of
this, both the putative MCL-1 inhibitors, BI97C1 and BI112D1,
induced ER membrane reorganization, albeit to modest extents com-
pared with apogossypol (Figure 2B and data not shown). However,
these inhibitors were very potent in inducing extensive mitochondrial
fragmentation (Figure 2), in agreement to the proposed role of MCL-1
in regulating mitochondrial fission-fusion dynamics [20]. Moreover,
BI112D1 exhibited a greater potency and induced a more rapid mito-
chondrial fragmentation than BI97C1 or ABT-263, in agreement with
the relative binding affinities of these inhibitors to MCL-1 (Figures 2
and 4D) [7,21,22,26]. This was further confirmed by RNA inter-
ference in H23 cells, which expressed both MCL-1 and BCL-w, with
barely detectable levels of BCL-XL and no BCL-2 ([14] and Fig-
ure W1). Although BCL-XL was not detected by Western blot analy-
sis (Figure W1), we carried out the experiment with the appropriate
siRNA because of the report stating the presence of very low levels of
BCL-XL in these cells [14]. Silencing the expression of MCL-1, but
not BCL-XL or BCL-w, resulted in mitochondrial fragmentation (Fig-
ure 2C ), although the effect was often masked by the extensive apop-
tosis that resulted within hours of MCL-1 down-regulation in the
MCL-1–dependent H23 cells (data not shown).
Mitochondrial fragmentation may be a consequence of either an
enhanced fission of the filamentous mitochondria or a loss in the fusion
events to form the lengthy and continuous mitochondrial network
[30–32]. The balance between these dynamic processes is brought
about by a family of GTPases, some of which regulate fission (DRP1),
while some favor mitochondrial fusion (OPA1 and MFNs) [30–32].
Mitochondrial fragmentation observed following several stimuli is
successfully inhibited by inactivating DRP1, either by using a specific
chemical inhibitor, Mdivi1, by silencing endogenous DRP1 expression,
or by overexpressing dominant negative mutants of DRP1 [39,40].
However, none of these approaches prevented the mitochondrial
Figure 7. MCL-1 inhibition by BI97C1, BI112D1, and ABT-263 results in mitochondrial fragmentation either upstream of or independent
of BAX/BAK-mediated apoptosis. Putative MCL-1 inhibitors may interfere with the antiapoptotic effects of MCL-1 resulting in the loss of
mitochondrial membrane potential and activation of MOMP, thus resulting in the intrinsic pathway of apoptosis. Alternatively, putative
MCL-1 inhibitors may interfere with other functions of MCL-1 including the postulated regulation of mitochondrial fusion, resulting in
mitochondrial fragmentation. The precise role(s) of ROS in mitochondrial fusion and fragmentation is unclear. BI97C1-, BI112D1-, and
ABT-263–mediated apoptosis require proapoptotic BAX/BAK and BIM/NOXA. Mitochondrial fragmentation occurred rapidly and either
upstream of or independent of BAX/BAK and BIM/NOXA. Thus, the two events—mitochondrial fragmentation and apoptosis—may
either be causally related or completely independent of each other. Nevertheless, MCL-1–regulated changes in mitochondrial fusion
occurred temporally before its antiapoptotic function.
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fragmentation mediated by BI97C1, BI112D1, or ABT-263 (Figure 3
and data not shown), arguing against the involvement of DRP1 in this
phenotype. Nevertheless, all these inhibitors caused a time-dependent
loss of the high molecular weight isoforms of OPA1 that precisely cor-
responded to the kinetics of mitochondrial fragmentation (Figure 4),
which raised the possibility thatMCL-1may regulateOPA1 loss possibly
by proteolysis, thereby regulating mitochondrial fusion. OPA1 exists in
eight isoforms resulting from alternative splicing with some isoforms
being evolutionary conserved and involved in fusion of themitochondrial
network [41,42]. Although we could not establish a direct interaction be-
tween MCL-1 and OPA1, they co-eluted on gel filtration analysis (data
not shown), raising the possibility that MCL-1 may be one component
of a complex responsible for OPA1 loss. Recent studies implicate a role
for different proteases, including metalloproteases and overlapping with
the m-AAA protease 1 (OMA1) in the proteolysis of OPA1 [43–46].
Attempts to prevent OPA1 proteolysis using o-phenanthroline [46], a
metalloprotease inhibitor, were unsuccessful because o-phenanthroline
alone resulted in excessive mitochondrial fragmentation (data not
shown). Furthermore, BI97C1, BI112D1, and ABT-263 induced mito-
chondrial fragmentation to a similar extent in both WT and OMA1
null MEFs (data not shown), which demonstrates that in this scenario
OMA1 is not responsible for mitochondrial fragmentation.
The precise mechanism whereby MCL-1 regulates mitochondrial
fragmentation is intriguing. Recently, the existence of two distinct
isoforms of MCL-1 with each isoform performing specific functions
with respect to mitochondrial fusion dynamics and apoptosis has been
proposed [20]. It is certainly possible for MCL-1 to perform functions
other than its well-characterized role, as an antiapoptotic BCL-2 family
member. Other BCL-2 family members have been reported to per-
form functions not directly related to their role in apoptosis [16,17].
It is feasible that different inhibitors target different MCL-1 isoforms
depending on binding affinities and/or cellular distribution and thus
may differentially affect the properties associated with these isoforms.
Thus, some inhibitors may preferentially affect the antiapoptotic role
of MCL-1, whereas others may have a greater effect on other functions,
such as mitochondrial fusion.
Changes in mitochondrial fusion-fission dynamics have frequently
been associated with apoptosis and are thought to occur downstream
of BAK and BAX, resulting in the loss of mitochondrial membrane
potential and release of cytochrome c and activation of the intrinsic
pathway of apoptosis [47]. To our knowledge, this is the first report
in which BCL-2 family antagonists induce mitochondrial fragmenta-
tion upstream of a loss in membrane potential and other hallmarks
of apoptosis (Figures 1 and 2). Although the inhibitors shifted the
dynamics from a filamentous mitochondrial network to fragmented
mitochondria, careful examination revealed that the fragmented mito-
chondria still retained intact outer and inner membranes (Figure 2B),
unlike the rupture of the outer mitochondrial membrane observed in a
novel paradigm of apoptosis following exposure of primary chronic
lymphocytic leukemia cells to ABT-737 and ABT-263, specific inhibi-
tors of BCL-2 and BCL-XL [27,48]. Furthermore, there was no
evidence of mitochondrial swelling or mitophagy, supporting the
notion that the mitochondria remained healthy despite a shift in the
fission-fusion dynamics, which may explain why the loss in membrane
potential and MOMP was not detected until much later. Although
one may expect that some functions of fragmented mitochondria
may be compromised, no changes in either complex IV, ATP synthase
oligomeric state, or ATP levels were observed (Figure 6, A and B, and
data not shown), whereas these parameters were affected in MCL-1–
deleted cells [20]. A permanent inability to fuse could result in the
accumulation of ROS and mutations of mtDNA, which could even-
tually kill the cells. Although we observed an accumulation of mito-
chondrial ROS, we were unable to ascertain if this was responsible
either for mitochondrial fragmentation or death, as several ROS scav-
engers (Trolox, N -acetylcysteine, and DTT) failed to reverse these
effects (data not shown).
In summary (Figure 7), we have established the selectivity of two
novel putative MCL-1 inhibitors, BI97C1 (Sabutoclax) and BI112D1,
in the induction of apoptosis in both a BAX/BAK-dependent manner
and in an MCL-1–dependent system. Using these inhibitors, support
for the role of MCL-1 in the regulation of mitochondrial fusion was
provided by the observation of extensive mitochondrial fragmenta-
tion accompanying an enhanced loss of OPA1, possibly by proteolyis.
This mitochondrial fragmentation occurred independently of DRP1-
mediated fission and, unlike most apoptotic stimuli, was observed
upstream of and/or independent of BAX, BAK, and other BH3-only
proteins and preceded other hallmarks of apoptosis. Further work is
required to understand the control, regulation, subcellular localization,
and functions of different isoforms of MCL-1. This will be aided by
the design and synthesis of isoform-specific inhibitors of MCL-1,
although current indications suggest that this may be extremely dif-
ficult. Such inhibitors could be particularly valuable in the treatment
of chemoresistant tumors, as well as shedding valuable insight into
the regulation of mitochondrial fusion.
Acknowledgments
We thank Judy McWilliam and Tim Smith for technical assistance and
the Medical Research Council for core support. We thank C. Pritchard
and A. Strasser for the cells.
References
[1] Chipuk JE and Green DR (2008). How do BCL-2 proteins induce mitochondrial
outer membrane permeabilization? Trends Cell Biol 18, 157–164.
[2] Danial NN and Korsmeyer SJ (2004). Cell death: critical control points. Cell 116,
205–219.
[3] Adams JM and Cory S (2007). The Bcl-2 apoptotic switch in cancer development
and therapy. Oncogene 26, 1324–1337.
[4] Youle RJ and Strasser A (2008). The BCL-2 protein family: opposing activities
that mediate cell death. Nat Rev Mol Cell Biol 9, 47–59.
[5] Lessene G, Czabotar PE, and Colman PM (2008). BCL-2 family antagonists for
cancer therapy. Nat Rev Drug Discov 7, 989–1000.
[6] Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA,
Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al. (2005). An inhibitor of
Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677–681.
[7] Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF,
Marsh KC, Mitten MJ, Nimmer P, et al. (2008). ABT-263: a potent and orally
bioavailable Bcl-2 family inhibitor. Cancer Res 68, 3421–3428.
[8] van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE,
Willis SN, Scott CL, Day CL, Cory S, et al. (2006). The BH3 mimetic ABT-737
targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if
Mcl-1 is neutralized. Cancer Cell 10, 389–399.
[9] Vogler M, Dinsdale D, Dyer MJ, and Cohen GM (2009). Bcl-2 inhibitors: small
molecules with a big impact on cancer therapy. Cell Death Differ 16, 360–367.
[10] Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJ, and
Cohen GM (2009). Different forms of cell death induced by putative BCL2
inhibitors. Cell Death Differ 16, 1030–1039.
[11] Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J,
Barretina J, Boehm JS, Dobson J, Urashima M, et al. (2010). The landscape
of somatic copy-number alteration across human cancers. Nature 463, 899–905.
[12] Dai Y and Grant S (2007). Targeting multiple arms of the apoptotic regulatory
machinery. Cancer Res 67, 2908–2911.
[13] Gores GJ and Kaufmann SH (2012). Selectively targeting Mcl-1 for the treatment
of acute myelogenous leukemia and solid tumors. Genes Dev 26, 305–311.
Neoplasia Vol. 15, No. 5, 2013 MCL-1 Regulates Mitochondrial Fragmentation Varadarajan et al. 577
[14] Zhang H, Guttikonda S, Roberts L, Uziel T, Semizarov D, Elmore SW,
Leverson JD, and Lam LT (2011). Mcl-1 is critical for survival in a subgroup
of non-small-cell lung cancer cell lines. Oncogene 30, 1963–1968.
[15] Warr MR and Shore GC (2008). Unique biology of Mcl-1: therapeutic opportu-
nities in cancer. Curr Mol Med 8, 138–147.
[16] Hardwick JM, Chen YB, and Jonas EA (2012). Multipolar functions of BCL-2
proteins link energetics to apoptosis. Trends Cell Biol 22, 318–328.
[17] Hetz C and Glimcher L (2008). The daily job of night killers: alternative roles
of the BCL-2 family in organelle physiology. Trends Cell Biol 18, 38–44.
[18] Karbowski M, Norris KL, Cleland MM, Jeong SY, and Youle RJ (2006). Role
of Bax and Bak in mitochondrial morphogenesis. Nature 443, 658–662.
[19] Sheridan C, Delivani P, Cullen SP, and Martin SJ (2008). Bax- or Bak-induced
mitochondrial fission can be uncoupled from cytochrome c release. Mol Cell 31,
570–585.
[20] Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, Temirov J,
Cleland MM, Pelletier S, Schuetz JD, et al. (2012). Anti-apoptotic MCL-1
localizes to the mitochondrial matrix and couples mitochondrial fusion to
respiration. Nat Cell Biol 14, 575–583.
[21] Wei J, Kitada S, Rega MF, Stebbins JL, Zhai D, Cellitti J, Yuan H, Emdadi A,
Dahl R, Zhang Z, et al. (2009). Apogossypol derivatives as pan-active inhibitors
of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med
Chem 52, 4511–4523.
[22] Wei J, Stebbins JL, Kitada S, Dash R, Placzek W, Rega MF, Wu B, Cellitti J,
Zhai D, Yang L, et al. (2010). BI-97C1, an optically pure Apogossypol deriva-
tive as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2)
family proteins. J Med Chem 53, 4166–4176.
[23] Dash R, Azab B, Quinn BA, Shen X, Wang XY, Das SK, Rahmani M, Wei J,
Hedvat M, Dent P, et al. (2011). Apogossypol derivative BI-97C1 (Sabutoclax)
targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24–mediated toxicity.
Proc Natl Acad Sci USA 108, 8785–8790.
[24] Jackson RS II, Placzek W, Fernandez A, Ziaee S, Chu CY, Wei J, Stebbins J,
Kitada S, Fritz G, Reed JC, et al. (2012). Sabutoclax, a Mcl-1 antagonist, inhibits
tumorigenesis in transgenic mouse and human xenograft models of prostate cancer.
Neoplasia 14, 656–665.
[25] Wei J, Kitada S, Stebbins JL, Placzek W, Zhai D, Wu B, Rega MF, Zhang Z,
Cellitti J, Yang L, et al. (2010). Synthesis and biological evaluation of Apogos-
sypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/
leukemia-2 (Bcl-2) family proteins. J Med Chem 53, 8000–8011.
[26] Wei J, Stebbins JL, Kitada S, Dash R, Zhai D, Placzek WJ, Wu B, Rega MF,
Zhang Z, Barile E, et al. (2011). An optically pure apogossypolone derivative as
potent pan-active inhibitor of anti-apoptotic bcl-2 family proteins. Front Oncol
1, 28.
[27] Vogler M, Dinsdale D, Sun XM, Young KW, Butterworth M, Nicotera P, Dyer
MJ, and Cohen GM (2008). A novel paradigm for rapid ABT-737-induced
apoptosis involving outer mitochondrial membrane rupture in primary leukemia
and lymphoma cells. Cell Death Differ 15, 820–830.
[28] Varadarajan S, Bampton ET, Smalley JL, Tanaka K, Caves RE, Butterworth M,
Wei J, Pellecchia M, Mitcheson J, Gant TW, et al. (2012). A novel cellular
stress response characterised by a rapid reorganisation of membranes of the
endoplasmic reticulum. Cell Death Differ 19, 1896–1907.
[29] Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney
DA, He SZ, Huang DC, Xiong H, et al. (2012). Substantial susceptibility of
chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of
navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30, 488–496.
[30] Hoppins S, Lackner L, and Nunnari J (2007). The machines that divide and
fuse mitochondria. Annu Rev Biochem 76, 751–780.
[31] Chen H and Chan DC (2005). Emerging functions of mammalian mitochondrial
fusion and fission. Hum Mol Genet 14 Spec No. 2, R283–R289.
[32] Westermann B (2008). Molecular machinery of mitochondrial fusion and
fission. J Biol Chem 283, 13501–13505.
[33] Berrieman HK, Smith L, O’Kane SL, Campbell A, Lind MJ, and Cawkwell L
(2005). The expression of Bcl-2 family proteins differs between nonsmall cell
lung carcinoma subtypes. Cancer 103, 1415–1419.
[34] Borner MM, Brousset P, Pfanner-Meyer B, Bacchi M, Vonlanthen S, Hotz MA,
Altermatt HJ, Schlaifer D, Reed JC, and Betticher DC (1999). Expression of
apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected
non-small-cell lung cancer. Br J Cancer 79, 952–958.
[35] Wesarg E, Hoffarth S, Wiewrodt R, Kroll M, Biesterfeld S, Huber C, and
Schuler M (2007). Targeting BCL-2 family proteins to overcome drug resistance
in non-small cell lung cancer. Int J Cancer 121, 2387–2394.
[36] Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju
SR, Goulet D, Viallet J, Belec L, Billot X, et al. (2007). Small molecule obatoclax
(GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to
apoptosis. Proc Natl Acad Sci USA 104, 19512–19517.
[37] Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ, and
Cohen GM (2009). Concurrent up-regulation of BCL-XL and BCL2A1 induces
approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.
Blood 113, 4403–4413.
[38] Varadarajan S, Tanaka K, Smalley JL, Bampton ETW, Pellecchia M, Dinsdale
D, Willars GB, and Cohen GM (2013). Endoplasmic reticulum membrane
reorganization is regulated by ionic homeostasis. PLos One 8, e56603.
[39] Cassidy-Stone A, Chipuk JE, Ingerman E, Song C, Yoo C, Kuwana T, Kurth
MJ, Shaw JT, Hinshaw JE, Green DR, et al. (2008). Chemical inhibition of
the mitochondrial division dynamin reveals its role in Bax/Bak-dependent
mitochondrial outer membrane permeabilization. Dev Cell 14, 193–204.
[40] Frank S, Gaume B, Bergmann-Leitner ES, Leitner WW, Robert EG, Catez F,
Smith CL, and Youle RJ (2001). The role of dynamin-related protein 1, a
mediator of mitochondrial fission, in apoptosis. Dev Cell 1, 515–525.
[41] Ishihara N, Fujita Y, Oka T, and Mihara K (2006). Regulation of mitochondrial
morphology through proteolytic cleavage of OPA1. EMBO J 25, 2966–2977.
[42] Olichon A, Elachouri G, Baricault L, Delettre C, Belenguer P, and Lenaers G
(2007). OPA1 alternate splicing uncouples an evolutionary conserved function
in mitochondrial fusion from a vertebrate restricted function in apoptosis. Cell
Death Differ 14, 682–692.
[43] Ehses S, Raschke I, Mancuso G, Bernacchia A, Geimer S, Tondera D, Martinou
JC, Westermann B, Rugarli EI, and Langer T (2009). Regulation of OPA1 pro-
cessing and mitochondrial fusion by m-AAA protease isoenzymes and OMA1.
J Cell Biol 187, 1023–1036.
[44] Head B, Griparic L, Amiri M, Gandre-Babbe S, and van der Bliek AM (2009).
Inducible proteolytic inactivation of OPA1 mediated by the OMA1 protease in
mammalian cells. J Cell Biol 187, 959–966.
[45] Quiros PM, Ramsay AJ, Sala D, Fernandez-Vizarra E, Rodriguez F, Peinado
JR, Fernandez-Garcia MS, Vega JA, Enriquez JA, Zorzano A, et al. (2012).
Loss of mitochondrial protease OMA1 alters processing of the GTPase
OPA1 and causes obesity and defective thermogenesis in mice. EMBO J 31,
2117–2133.
[46] Duvezin-Caubet S, Jagasia R, Wagener J, Hofmann S, Trifunovic A, Hansson
A, Chomyn A, Bauer MF, Attardi G, Larsson NG, et al. (2006). Proteolytic
processing of OPA1 links mitochondrial dysfunction to alterations in mito-
chondrial morphology. J Biol Chem 281, 37972–37979.
[47] Youle RJ (2005). Morphology of mitochondria during apoptosis: worms-to-
beetles in worms. Dev Cell 8, 298–299.
[48] Vogler M, Furdas SD, Jung M, Kuwana T, Dyer MJ, and Cohen GM
(2010). Diminished sensitivity of chronic lymphocytic leukemia cells to
ABT-737 and ABT-263 due to albumin binding in blood. Clin Cancer Res 16,
4217–4225.
578 MCL-1 Regulates Mitochondrial Fragmentation Varadarajan et al. Neoplasia Vol. 15, No. 5, 2013
Figure W1. Efficient knockdown of BCL-2 family proteins. Western blots showing the knockdown efficiency of the siRNA oligoduplexes
in H23 cells reverse transfected for 16 hours with siRNA against (A) MCL-1, BCL-XL, or BCL-w or (B) BIM or NOXA. Tubulin was used as
a loading control.
Figure W2. BI97C1-, BI112D1-, and ABT-263–mediated mitochondrial fragmentation occurs before changes in mitochondrial membrane
potential. H23 cells exposed to 10 μM ABT-263, BI97C1, or BI112D1 for 2 to 16 hours were stained with MitoTracker Deep Red (to
monitor fragmentation) and TMRE (to monitor changes in membrane potential) for 30 minutes before image acquisition (scale bar,
10 μm). Mitochondrial fragmentation occurred before loss of mitochondrial membrane potential, which was particularly evident in cells
exposed to BI112D1.
